Comparative Pharmacology
Head-to-head clinical analysis: EMFLAZA versus PEDIAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMFLAZA versus PEDIAPRED.
EMFLAZA vs PEDIAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Prednisolone is a glucocorticoid receptor agonist that binds to the intracellular glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production (e.g., IL-1, IL-6, TNF-alpha). It also suppresses immune responses by reducing lymphocyte proliferation and activity.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
Oral: 5-60 mg/day as a single dose or divided doses; adjust based on condition and response.
None Documented
None Documented
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
2.5–3.5 hours (terminal) in children; clinical context: requires multiple daily doses for sustained effect.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Renal: ~80% as metabolites (mainly glucuronides and sulfates) and <5% unchanged; fecal: ~15%.
Category C
Category C
Corticosteroid
Corticosteroid